Neurocrine Biosciences | NBIX - Equity Capital And Reserves


Neurocrine Biosciences reported $3.41B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
ALKERMES USD 1.75B 67.76M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Cytokinetics USD -826.57M 166.94M Mar/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Exelixis USD 1.94B 225.57M Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Prothena USD 312.62M 32.14M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Repligen USD 2.11B 666K Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Teva Pharmaceutical Industries USD 8.23B 314M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026